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Background: Point mutations in mitochondrial genome cause severe clinical disorders.
Results:We designed recombinant RNAmolecules imported into mitochondria of human cells, which are able to decrease the
proportion of mitochondrial DNA molecules bearing a pathogenic point mutation.
Conclusion: Imported recombinant RNAs can function as anti-replicative agents in human mitochondria.
Significance: This is a new approach for therapy of mitochondrial diseases.
Defects in mitochondrial genome can cause a wide range of
clinical disorders,mainly neuromuscular diseases. Presently, no
efficient therapeutic treatment has been developed against this
class of pathologies. Because most of deleterious mitochondrial
mutations are heteroplasmic, meaning that wild type and
mutated forms of mitochondrial DNA (mtDNA) coexist in the
same cell, the shift in proportion betweenmutant and wild type
molecules could restore mitochondrial functions. Recently, we
developed mitochondrial RNA vectors that can be used to
address anti-replicative oligoribonucleotides into human mito-
chondria and thus impact heteroplasmy level in cells bearing a
large deletion inmtDNA.Here,we show that this strategy canbe
also applied to pointmutations inmtDNA.Wedemonstrate that
specifically designed RNA molecules containing structural deter-
minants for mitochondrial import and 20-nucleotide sequence
corresponding to the mutated region of mtDNA, are able to
anneal selectively to the mutated mitochondrial genomes.
After being imported into mitochondria of living human cells
in culture, these RNA induced a decrease of the proportion of
mtDNA molecules bearing a pathogenic point mutation in
the mtDNA ND5 gene.
RNA is increasingly used in therapeutic applications, includ-
ing the agents of RNA interference, catalytically active RNA
molecules, and RNA aptamers that bind proteins and other
ligands (reviewed in Ref. 1). Here, we use RNA molecules
imported into human mitochondria to suppress negative
effects of mutations in mtDNA.4 Involved in many metabolic
pathways varying from cellular respiration to apoptosis, mito-
chondria are subcellular organelles essential for eukaryotic cells
containing their proper genome, mtDNA. Human mtDNA is a
closed circular double-strandedmolecule of 16.5 kb able to rep-
licate autonomously and encoding only 13 polypeptides, two
ribosomal RNA (12 S and 16 S), and 22 tRNA, with the vast
majority of mitochondrial proteins and several RNAs being
encoded in the nucleus and imported from the cytoplasm.Mul-
tiple alterations may occur in the mitochondrial genome (dele-
tions, duplications, and point mutations), resulting in severe
impact on cellular respiration and therefore leading to many
diseases, essentially muscular and neurodegenerative disor-
ders. To date, 250 pathologic diseases were shown to be
caused by defects in mtDNA (2). The majority of these muta-
tions are heteroplasmic, meaning that mtDNA coexists in two
forms, wild type and mutated, in the same cell. The occurrence
and severity of pathologic effects depend on the heteroplasmy
level, clinical symptoms appearing at the threshold of the order
of 60 to 80%, depending on the mutation and the type of cells
(3).
Various strategies have been proposed to address these
pathologies, unfortunately, for the vast majority of cases, no
efficient treatment is currently available. In some cases, defects
may be rescued by targeting into mitochondria nuclear DNA-
expressed counterparts of the affected molecules, an approach
called allotopic strategy (4, 5). Allotopic expression of mtDNA-
encoded polypeptides has been demonstrated in yeast, but in
mammalian mitochondria, results are contradictory (reviewed
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in Ref. 6). We have exploited the RNA mitochondrial import
pathway, which is the only known natural mechanism of
nucleic acid delivery into mitochondria (reviewed in Ref. 7), to
develop two successfulmodels of allotopic rescue of anmtDNA
mutation by targeting recombinant tRNA into mitochondria
(8, 9).
Another strategy that might be termed as “anti-genomic,”
which consists of addressing into mitochondria endonucleases
specifically eliminating mutated mtDNA, was also described
(10, 11). Another approach, referred to as anti-replicative, aims
to induce a shift in heteroplasmy level by targeting specifically
the replication of mutant mtDNA, thus giving a propagative
advantage to wild type genomes. This strategy has first been
tested in vitro using peptide nucleic acids with high affinity to
mutant mtDNA (12). It was demonstrated that peptide nucleic
acid oligomers complementary to mutant mtDNA can specifi-
cally inhibit its replication in vitro; however, it remained non-
applicable to living cells because of the impossibility of intro-
ducing peptide nucleic acid molecules into mitochondria in
vivo (13). To overcome this obstacle, we proposed to use RNA
mitochondrial import.
Analysis of the yeast tRNALysCUU mitochondrial import
mechanism demonstrated that binding to mitochondrial tar-
geting protein factors and subsequent RNA translocation
acrossmitochondrialmembranes require formation of an alter-
native structure, different from a classic L-form tRNA model,
characterized by bringing together the 3-end and TC loop
and forming the structure referred to as F-hairpin. Exploiting
these data, we designed a short synthetic RNA comprising two
domains of the yeast tRNALysCUU alternative structure, D-arm
and F-hairpin (referred to as FD RNA) (see Fig. 1), character-
ized by a high efficiency of mitochondrial targeting (14). These
molecules, fused to oligonucleotide stretches complementary
to the mtDNA-mutated region, were able to shift a hetero-
plasmy level in cells containing a large deletion inmtDNA, pro-
viding the first validation of the anti-replicative approach in
vivo (15).
Here, we show that this approach is not limited to large rear-
rangements in mtDNA but can be applied to point mutations.
We provide a protocol to design an oligonucleotide able to
anneal tomtDNAbearing a pointmutation but not to wild type
mtDNA and an original assay to test the specificity of hybrid-
ization in vitro. A series of recombinant molecules, including
RNA-DNA chimera, have been tested for mitochondrial
import in human cultured cells and their ability to induce a shift
of the heteroplasmy level.Wedemonstrate that RNAmolecules
containing mitochondrial targeting determinants and a 20-nu-
cleotide sequence corresponding to the mutated region of
mtDNA are able to selectively target mutated mitochondrial
genomes. After being imported into mitochondria of cultured
trans-mitochondrial human cells bearing a pathogenic point
mutation in ND5 gene, these RNA significantly decreased the
proportion of mutated mtDNA molecules.
EXPERIMENTAL PROCEDURES
Recombinant RNAModeling and Synthesis—To predict sec-
ondary structures of recombinant RNA and estimate their free
energy (dG), theMfold (16), IDT Sci-Tools OligoAnalyser (ver-
sion 3.1), and ViennaRNA platforms were used. To estimate
melting temperatures forDNA-DNAandRNA-DNAduplexes,
we used IDT Sci-Tools OligoAnalyser software (version 3.1)
(17).
The recombinant RNAs were obtained by T7 transcription
using the T7 RiboMAX Express Large Scale RNA Production
System (Promega) on the corresponding PCR products and
were gel-purified. For PCR, the following oligonucleotides con-
taining a T7 promoter (underlined) were used: FD16L (5-TAA
TAC GAC TCA CTA TAG CGC AAT CGG TAG CGC ACT
CCA AAG GCC ACA TGA GCC CCC TAC AGG GCT C-3);
FD16H (5-TAA TAC GAC TCA CTA TAG CGC AAT CGG
TAG CGC ATG TGG CCT TTG GAG TGA GCC CCC TAC
AGG GCT C-3); FD20L (5-TAA TAC GAC TCA CTA TAG
CGC AAT CGG TAG CGC ACT CCA AAG GCC ACA TCA
TCG AGC CCC CTA CAG GGC TC-3); FD20H (5-TAA
TAC GAC TCA CTA TAG CGC AAT CGG TAG CGC GAT
GAT GTG GCC TTT GGA GTG AGC CCC CTA CAG GGC
TC-3); FD25L (5-TAATACGACTCACTATAGCGCAAT
CGG TAG CGC GTT TCT ACT CCA AAG GCC ACA TCA
TGA GCC CCC TAC AGG GCT C-3); FD25H (5-TAA TAC
GAC TCA CTA TAG CGC AAT CGG TAG CGC ATG ATG
TGG CCT TTG GAG TAG AAA CGA GCC CCC TAC AGG
GCT C-3) with primers T7 (5-GGG ATC CAT AAT ACG
ACT CAC TAT A-3) and FD-rev (5-AAG AGC CCT GTA
GGG-3).
To test recombinant RNA annealing to target mtDNA, frag-
ments of wild type and mutant mtDNA were amplified using
primers hmtGluRT (5-GTT CTT GTAGTT GAA ATA C-3)
and CRC-F (5-CAT ACC TCT CAC TTC AAC CTC C-3),
separated on 1% agarose gel, blotted to Hybond-N membrane,
and hybridized with 32P-labeled recombinant RNAs in 1 PBS
at 37 °C. After PhosphorImager quantification (Typhoon Trio,
GE Healthcare), the hybridization signals were normalized to
amounts of corresponding mtDNA fragments calculated after
ethidium bromide staining of the agarose gel (before transfer
to Hybond membrane) by densitometry using G-Box and
GeneTools analysis software. Thereafter, hybridization speci-
ficity was calculated for each RNA as one minus ratio between
normalized signals for wild type and mutated DNA fragments.
Thus, for recombinant RNA annealed only to mutant DNA
fragment, the hybridization specificity value reached 1, and for
RNA annealed equally to mutant and wild type fragments, this
value was close to 0. At least three independent experiments
were performed for each RNA.
Chimeric Oligonucleotide Synthesis—Chimeric oligonucleo-
tides D20L DNA and D20HDNAwere synthesized on an auto-
matic ASM-800 RNA/DNA synthesizer (Biosset) at 0.4-mol
scale using solid phase phosphoramidite synthesis protocols
(18) optimized for this instrument. The DNA and 2-O-
TBDMS (tert-butyldimethylsilyl)-protected RNA phosphor-
amidites and appropriate supports were purchased from Glen
Research. A 5-ethylthio-H-tetrazole has been used as activator
with 5- and 10-min coupling steps, respectively. After standard
deprotection, oligonucleotides were purified by 12% polyacryl-
amide/8 M urea gel and characterized by MALDI-TOF mass
spectrometry (Autoflex III, Bruker Daltonics).
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Synthesis of Fluorescently Labeled RNA Transcript—Alexa
Fluor 488-5 UTP (Molecular Probes) was incorporated into
RNA during 2-h T7 transcription by T7 RNA polymerase (Pro-
mega). A reaction mixture of 20 l total volume contained 0.5
g of DNA template, 80 units of T7-RNA polymerase (two
additions of 40 units each), 0.5 mM ATP, 0.5 mM CTP, 0.5 mM
GTP, 0.37 mM UTP, 0.125 mM Alexa Fluor 488-5-UTP, 10 mM
DTT, and 40 units of RNaseOUT (Invitrogen). T7 transcript
was purified by PAGE. To check the incorporation of the label
in purified transcript, we compared the dye absorbance at 492
nm with the absorbance at 260 nm using NanoDrop ND1000
Microarray software (version 3.5.2). The efficiency of labeling
obtained was approximately two labeled uridines per one RNA
molecule.
RNA FD20H, used for the microscopy, contains 13 uridine
residues (see Fig. 2): one at the end of F-stem region, three in the
loops, and nine in the anti-replicative part of the molecule,
which is not responsible for the mitochondrial import effi-
ciency. Therefore, the labeling should not significantly alter the
secondary structure and mitochondrial import of the RNA
molecule.
Transient Transfection of Cybrid Cells—Trans-mitochon-
drial cybrid cell lines obtained by fusion of fibroblast-derived
cytoplast from patient and a 143B rho0 cell line (19) were kindly
provided byM. Zeviani (National Neurological Institute “Carlo
Besta,” Milan, Italy).
Primary skin fibroblasts were from patient 1: a boy born to
non-consanguineous healthy parents. He was completely nor-
mal until 13 years of age when he developed dystonia of the left
hand that worsened progressively. A brain MRI at 14 years of
age revealed hypersignal of basal ganglia and abnormalities of
brain system consistent with the diagnosis of Leigh syndrome.
Two years later, he had tonicoclonic seizures with nystagmus
and dysarthria. Stroke-like pattern was detected by brain MRI.
Measurement of respiratory chain activities detected an iso-
lated complex I deficiency related to a mitochondrial DNA
mutation in the ND5 gene (A13514G). Fibroblasts were char-
acterized by a 30% heteroplasmy level. Cells were cultivated at
37 °C and 5% CO2 in DMEM (Sigma) containing 4.5 g/liter of
glucose supplemented with fetal calf serum (Invitrogen), peni-
cillin/streptomycin, uridine (50 mg/liter), and fungizone (2.50
mg/liter) (Invitrogen).
Transient transfection of cells with RNA and chimeric mol-
ecules was performed as described in Refs. 20 and 21 with some
modifications: for 2 cm2 well of 80% confluent cells, we used
0.25 g of RNA and 1 l of Lipofectamine 2000 in OptiMEM
medium (Invitrogen). OptiMEM was changed to a standard
DMEM medium 8 h after transfection. In these conditions,
80% of fibroblasts and 95% of cybrid cells were transfected
with RNA (evaluated by fluorescent microscopy and by flow
cytometry using CyFlow FACS 24 h post transfection).We also
comparedNorthern hybridization signals obtained on total cel-
lular RNA and on the known amounts of T7 transcripts loaded
on the same gel.We could estimate that15% of RNA added to
cybrid cells and 20% RNA for fibroblasts were internalized and
can be detected in full-size form24 h post transfection (data not
shown). Transfection procedure did not lead to detectable
decrease of viability of the cells or to a significant change of the
overall mtDNA amount verified by real-time quantitative PCR
as described (15).
RNA Stability and Mitochondrial Import in Vivo—Mito-
chondria were isolated from the cybrid cells as described pre-
viously (22, 23) and treated with digitonin to generate mito-
plasts (mitochondria devoid of the outer membrane) and
RNaseA to get rid of non-specifically attachedRNA.This treat-
ment allows us to obtain mitochondria free of cytosolic RNA
contamination, which was tested using a probe for cytosolic
5.8 S rRNA usually strongly attached to the outer mitochon-
drialmembrane. Total andmitochondrial RNAwas isolatedwith
TRIzol reagent (Invitrogen). Stability andmitochondrial import of
recombinant molecules were analyzed by Northern hybridization
of total and mitochondrial RNA with 32P-labeled oligonucleotide
probes followed by PhosphorImager quantification (Typhoon-
Trio, GEHealthcare).
The probes used were as follows: “D-loop” probe-specific for
recombinant molecules (see Fig. 1), 5-GAG TCA TAC GCG
CTA CCG ATT GCG CCA ACA AGG C-3, hybridization
temperature of 50 °C; cytosolic 5.8S rRNAprobe, 5-GGCCGC
AAG TGC GTT CGA AG-3, hybridization temperature of
50 °C; probe against the mitochondrial tRNAVal, 5-GAA CCT
CTG ACT GTA AAG-3, hybridization temperature of 45 °C;
probe against the nuclear snRNA U3, 5-CGC TAC CTC TCT
TCC TCG TGG-3, hybridization temperature of 50 °C. To
compare the stability of different recombinant RNA, the rela-
tive concentration of each RNA in various time periods after
transfection was calculated as a ratio between the D-loop probe
signal and the signal for cytosolic 5.8 S rRNA.
The relative amount of each imported RNA inside the mito-
chondria was estimated as a ratio between the signal obtained
after hybridization with the D-loop probe and the signal with a
probe against the mitochondrial tRNAVal in the same RNA
preparation. To compare import efficiencies of different RNA
molecules, the total level of each RNA molecule in transfected
cells was taken into account and normalized as described pre-
viously (22). At least three independent experiments were per-
formed for each RNA.
Confocal Microscopy—Cybrids cells cultivated in 2-cm2
chamber slides (Lab-Tek) were transfected with Alexa Fluor
488-5-UTP-labeled RNA. At different time periods after trans-
fections, living cells were stained with 5 M tetramethylrhod-
amine methyl ester (TMRM) for 15 min at 37 °C, washed, and
imaged in DMEM without red phenol. The LSM 700 confocal
microscope (Zeiss) was used in conjunction with Zen imaging
software, and images were acquired with a Zeiss 63/1.40 oil
immersion objective with a resolution of 1024  1024. The
excitation/emission laser wavelengths were 488 nm (green
channel) and 555nm (red channel). Imageswere analyzed using
ImageJ software (24) and JACoP plugin (25). Co-localization
analyses were performed onmultiple cells and optical sections.
Pearson’s and Manders’ coefficients were estimated (26, 27).
Pearson’s correlation coefficient provides ameasure of correla-
tion between the intensities of each channel in each pixel. The
overlap coefficients according to Manders indicate an actual
overlap of the signals and represent the true degree of co-local-
ization. In control experiments, cells were transfected with
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Alexa Fluor 488-5-UTP-labeled RNA, which is not imported
into mitochondria (28).
mtDNA Heteroplasmy Level Analysis—To isolate total DNA
from transfected cells, 1 cm2 of cells were solubilized in 0.5 ml
of buffer containing 10 mM Tris-HCl, pH 7.5, 10 mM NaCl, 25
mMNa-EDTA, and 1% SDS, then 10l of proteinase K solution
(20mg/ml) was added, and themixture was incubated for 2 h at
50 °C; 50 l of 5 M NaCl was added, the DNA was precipitated
with isopropyl alcohol and used for PCR amplification. Hetero-
plasmy level was analyzed by restriction fragment length poly-
morphism on a 125-bp PCR fragment encompassing nucleo-
tides 13430 to 13555 of mtDNA obtained with primers CRC-F
5-CAT ACC TCT CAC TTC AAC CTC C-3 and CRC-R
5-AGG CGT TTG TGT ATG ATA TGT TTG C-3 (19). The
A13514G mutation creates a HaeIII-specific cleavage site, giving
two fragments of 80 and 45 bp. The HaeIII-digested fragments
were separated on a 10% PAGE and stained with ethidium bro-
mide. The proportion of mutant versus total mtDNA was calcu-
lated by densitometry using G-Box and GeneTools analysis soft-
ware (Syngene). At least four independent transfections were
performed with each recombinant RNA. Each DNA sample was
analyzed twice by PCR amplification followed by at least three gel
separation and quantification experiments.
The digestion control was performed for each reaction. For
this, a 600-bp PCR fragment encompassing nucleotides 1216 to
1813 of mtDNA obtained with the primers CRS-F (5-CGA
TAAACCCCGATCAACCTC-3) andCRS-R (5- GGTTAT
AAT TTT TCA TCT TTC CC-3) was cleaved by HaeIII to
350- and 250-bp fragments in the same tube as 125-bp PCR
fragment containing the A13514G mutation site.
Mitochondria Quantification—2-cm2 wells of 80% confluent
cybrid cells and control wild type 143B cells, transfected with
FD20H RNA, were stained with 5 M TMRM and 200 nM
MitoTracker Green during 15 min in culture medium. The
intensity of fluorescence was directly measured in a culture
plate in DMEM without red phenol by VICTORTM X3 multi-
label plate reader (PerkinElmer Life Science) at 485 nm (green
channel) and 555 nm (red channel) in triplicate for each sample.
After fluorescence measurement, cells were detached and
quantified by flow cytometry using CyFlow FACS and FloMax
software (Partec). Activity of complex I was measured using a
MitoSciences kit (Abcam).
Statistical Analyses—Pairwise comparisons were performed
using two-tailed Student’s t test and Excel software (Microsoft).
Data are expressed as means S.D.
RESULTS
Design of Anti-replicative RNA Molecules—As it was re-
ported previously, the helix-loop domains of FDRNA can serve
as signals for RNAmitochondrial import, and thismolecule can
be used as a vector to deliver various sequences into the organ-
elles (15). Recently, we also demonstrated that only one D-arm
structure can be sufficient for targeting of recombinant mole-
cule to mitochondria in living cells (28, 29).
To apply the anti-genomic strategy to point mutations, we
used as a model the A13514G mutation inducing amino acid
replacement D393G in theND5 gene of humanmtDNA, which
encodes one of the membrane domain subunits of the respira-
tory complex I (30). This mutation was initially found in two
unrelated patients with MELAS (mitochondrial encephalopa-
thy, lactic acidosis, and stroke-like episodes)-like syndrome
(19). To target the mutant mitochondrial genome, a series of
RNA molecules were constructed, bearing sequences comple-
mentary to amutated region ofND5 gene inserted between two
helix-loop domains of a short artificial FD RNA (Fig. 1).
First, we analyzed the secondary structure predictions for FD
RNAmolecules bearing insertions of 16, 20, and 25 nucleotides
corresponding to a fragment of the ND5 gene, referred to as
FD16L, FD16H, FD20L, FD20H, FD25L, and FD25H; R for
sequence of H-strand and S for L-strand of mtDNA. For each
sequence, a series of insertions bearing nucleotide G or C cor-
responding to the mutation A13514G (for either H- or
L-strand) in various positions (Fig. 1) were analyzed by several
types of software (see “Experimental Procedures”) with similar
results. Only molecules with a low probability of alternative
folding were retained for further studies (Fig. 1). To check the
ability of the selected versions for a specific annealing with
mutated, but not wild typemtDNA, labeled recombinant RNAs
were hybridized under physiological conditions with PCR-am-
plifiedmtDNA fragments either containing themutation or not
(Fig. 2). Versions FD25L and FD25H were not able to discrim-
inate between mutant and wild type mtDNA; the shorter RNA
molecule FD20H (but not FD20L) demonstrated specific
annealingwith theA13514GbearingmtDNAbut not wild type.
Annealing of molecules FD16H and FD16L was rather specific
for mutant mtDNA; however, the efficiency of their hybridiza-
tion at 37 °C was reproducibly lower when compared with
FD20H.We also tested chimeric molecules, containing a stem-
loop RNA import determinant andDNA inserts corresponding
to FD20HandFD20L sequences, referred to asD20H-DNAand
D20L-DNA (Fig. 2). Chimeric RNA-DNA molecule D20L-
DNA demonstrated a higher ability to discriminate between
mutant and wild type mtDNA when compared with FD20L.
Thus, the recombinantmolecules with 20 nucleotide insertions
(FD20L, FD20H, D20L-DNA, and D20H-DNA) have been
selected for the further analysis.
Mitochondrial Import of Recombinant RNA—To study the
localization of recombinant RNAmolecules in cultured human
cells, an approach was developed consisting in cell transfection
with Alexa Fluor 488-labeled RNA FD20H and its subsequent
co-localization with the mitochondrial network by means of
fluorescent confocal microscopy (Fig. 3). RNA molecules
(green fluorescence) were detectable in cells in 24 h after trans-
fection (day 1) as green dots, most probably representing the
RNA-Lipofectamine complexes, with only slight co-localiza-
tionwith themitochondria (red fluorescence). In 2–4days after
transfection, the distribution of the green label changed drasti-
cally, the amount of dotswas reduced, andRNAmoleculeswere
now mostly dispersed within the cell, displaying clear partial
co-localization with the mitochondrial network (Fig. 3B and
supplemental movies). To perform quantitative co-localization
analysis of confocal microscopy images, we estimated the val-
ues of Pearson’s correlation coefficient and Manders’ overlap
coefficients M1 and M2 (26). For control RNA that is not
imported into mitochondria (28), all of the coefficient values
were very low (Fig. 3A), thus excluding the coincidental overlap
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of green and red signals. For FD20H RNA, the M1 values indi-
cated that in 2 days post transfection, 50% of green fluores-
cence (RNA) has been co-localized with red fluorescence
(mitochondria), and this level did not significantly change
between 2 and 4 days post transfection.M2 values representing
the percentage of the red fluorescence (mitochondria) overlap-
FIGURE 1. Design of anti-replicative RNAs targeting A13514G mutation in human mtDNA. Human mtDNA genetic map and sequence of the mutated
region of ND5 gene are presented, A13514G mutation is shown in boldface type; the FD-RNA stem-loop import determinants are colored gray. Design of
recombinant RNA FD20H containing 20-mer corresponding to the H-strand of mtDNA is shown (see text for details).
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ping with the green fluorescence (RNA) indicate that only 10%
of mitochondria contained RNA in 2 days post transfection.
This proportion has been increased in 3 and 4 days up to 70%,
probably due to the mitochondrial dynamic events, fusion and
fission, resulting in more homogenous RNA distribution.
These data clearly indicate on mitochondrial targeting of
FD20H RNA in living human cells.
To measure recombinant RNA stability in cultured cells and
the efficiency of their import into the mitochondrial matrix,
cybrid cells were transfected with in vitro-synthesized recom-
binant RNAs and chimericmolecules. Their degradation rate in
transfected cells was evaluated by Northern hybridization of
total cellular RNA at different time points spanning a 6-day
period after transfection (Fig. 4A). Recombinant molecules
were detectable in cybrid cells at least 6 days after transfection.
The chimeric version D20L DNA revealed to be more stable
than FD20L and FD20H. Such result suggests that the “inser-
tion” part, lacking strong secondary structures, gives a promi-
nent impact on the degradation of recombinant molecules.
Thus, recombinant molecules in which RNA insertions were
replaced by DNA sequences demonstrated improved stability
in the living cells.
Because themicroscopy data can give only a rough indication
on the mitochondrial import of RNAmolecules, we performed
FIGURE2.Ability of recombinantmolecules todiscriminatewild typeandmutantmtDNA.A, predicted secondary structures of anti-replicativemolecules.
Stem-loop import determinants are shown in gray. D20HDNA andD20LDNA, chemically synthesized chimericmolecules, RNA insertion has been replaced by
DNA. B, Southern hybridization of WT or mutant (A13514G) mtDNA fragments with labeled recombinant RNAs (indicated at the left) under physiological
conditions. Long exp., radiogram after longer exposition for FD16H and FD16L. The specific radioactivity of all of the RNA probes was comparable. C, graphical
representation of hybridization specificity of different recombinant molecules (indicated below the graphs). The hybridization specificity was calculated for
each RNAas 1 (ratio betweenhybridization signals forwild type andmutatedDNA fragments). Thus, for recombinant RNAannealed only to themutantDNA
fragment, the hybridization specificity value reached 1, and for RNA annealed equally tomutant andwild type fragments, this valuewas close to 0. Data are
S.D. calculated from three independent experiments.
FIGURE 3. Confocal microscopy of human cells transfected with fluorescently labeled RNA. A, confocal microscopy of 143B cells transfected with Alexa
Fluor 488-labeled FD20H RNA (green) at various time periods after transfection (as indicated above the panels). Control, cells transfected with Alexa Fluor
488-5-UTP-labeled RNA, which is not imported into mitochondria, 3 days post transfection. TMRM, visualization of mitochondrial network by red staining.
Below the panels, shown is quantification of RNA co-localizationwithmitochondria, estimated formultiple cells and 6–10 optical sections in two independent
experiments. PC, Pearson’s correlation coefficient;M1 andM2, Manders’ overlap coefficients, representing the percentage of green fluorescence co-localized
with red fluorescence (for M1) and the percentage of red fluorescence co-localization with green fluorescence (for M2). B, magnification of the image
corresponding to day 4 post transfection. A three-dimensional reconstruction of the confocal microscopy image by ImageJ software is presented in the
supplemental movies.
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Northern blot hybridization experiments. For this, cells were
transfected with purified recombinant molecules. The mito-
chondrial import was analyzed by hybridization of the whole
cell RNA and RNA isolated from purified and RNase-treated
mitoplasts (mitochondria where the outer membrane was
removed by digitonin) as described previously (15, 22, 29). The
absence of signal in the mitochondrial RNA preparation after
hybridization with the probe against the cytoplasmic 5.8 S
rRNA indicates that the treatment of mitochondria with ribo-
nuclease and digitonin removed all contamination by cytoplas-
mic RNA (Fig. 4B). Hybridization signals obtained with the
D-loop probe specific for all of the recombinantmolecules were
normalized to the amounts of loaded RNA, estimated by hybrid-
izationwith a probe to amitochondrial transcript (mito tRNAVal).
The data show that the import efficiencies of RNA molecules
FD20H and FD20Lwere close to each other; import of the chime-
ric molecule D20L-DNAwas only slightly decreased (Fig. 4B).
Imported RNACan Shift Point Mutation Heteroplasmy Level
in Cybrid Cells—Trans-mitochondrial cybrid cell line contain-
ing a patient’s mitochondria with 35% of mtDNA molecules
bearing an A13514G mutation (referred thereafter as ND5
mutation) were transfected with in vitro synthesized recombi-
nant RNA and chimeric RNA-DNA molecules. Heteroplasmy
levels (percentage of mutant ND5mtDNA to all mtDNA mol-
ecules) were measured at different time points after transfec-
tion by restriction fragment length polymorphism analysis of
FIGURE 4.Anti-replicativeRNAstability andmitochondrial import in transiently transfected cybrid cells.A, an example ofNorthern hybridization of total RNA
isolated in3–6daysaftercell transfection (as indicatedbelow)withvarious recombinantmolecules (indicatedabove thepanels). Probesused forhybridization:D-loop,
specific for all recombinantmoleculesused for transfection;5S, against 5 S rRNA toquantify the level of recombinantRNA in thecells. TimedependenceofRNAdecay
is shownbelow (means S.D. calculated from at least four independent experiments). B, mitochondrial import of recombinantmolecules in transiently transfected
cybrid cells.NorthernhybridizationsofRNAextracted fromcells (Total RNA) orpurifiedmitoplasts (MitoRNA) 48hafter transfection.Above, RNAsused for transfection
are indicated.On the left, hybridizationprobes: D-loop, specific for recombinantmolecules used for the transfection;Cyt 5.8S, against 5.8 S rRNA to check the absence
of cytosolic RNA in mitochondrial samples; snRNA U3, demonstrating that the mitoplast fraction was not contaminated by the small nuclear RNAs; Mit tRNAVal, to
normalize the level of recombinant RNA to amount of loadedmaterial. Import efficiencywas estimated as a ratio ofmitochondrial to total signal for the D-loopprobe
after normalization of the both signals to those formitochondrial tRNAVal probe.
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PCR-amplified mtDNA fragment (Fig. 5, A and B). We
observed a reproducible decrease of the proportion of mutant
mtDNA in cells transfected by recombinant RNA containing
FD20H inserts. The heteroplasmy shift became visible 3 days
after transfection, and then the heteroplasmy continued to
decrease and reached the stable level of 13 2% in 6 days post
transfection. To affirm these data, we performed transfection of
patient’s fibroblasts, harboring the A13514G mutation, with
FD20H RNA (Fig. 5, A and B). This completely indepen-
dent experiment on primary human cells gave the same result
of heteroplasmy shift, as obtained on the cybrid cells model.
Remarkably, in cells transfected with FD20H RNA, the
decrease of mutant mtDNA correlated to increased amount of
mitochondria per cell measured asMitoTracker Green fluores-
cence (Fig. 5C). Moreover, the same increase of the fluores-
cencewas detected by TMRMdye that is readily sequestered by
active mitochondria, indicating on a fully energized state of
mitochondrial membranes (31).
In parallel experiments, mock-transfected cybrid cells dem-
onstrated no heteroplasmy shift (Fig. 5,A and B). Cell transfec-
tion with FD20L RNA led to a very small heteroplasmy
decrease, reaching the level of 27  5% in 7 days (Fig. 5A).
Different effects of FD20H and FD20L RNA molecules are in
perfect correlation with the more specific hybridization of
FD20HRNAwithmutantmtDNA (Fig. 2). Surprisingly, chime-
ric molecule D20L DNA, characterized by a rather specific
hybridization with mutant mtDNA in vitro, high stability in
cells, and efficient import into mitochondria, was not able to
influence the heteroplasmy level. Our data show that mito-
chondrially imported RNA (but not DNA) molecules can func-
tion as anti-genomic agents in human cells, affecting the
amount of mitochondrial genomes bearing a point mutation.
DISCUSSION
Specific Annealing of RNA to mtDNA Bearing a Point Mu-
tation—The anti-replicative approach aiming to shift hetero-
plasmy levels in mtDNA below the pathogenic threshold has
been recently applied to cells containing a large 7-kb deletion in
mtDNA (15). In this case, a new sequence generated at the
fusion of the deletion boundaries has been inserted into RNA
vector molecules, and specific annealing only with the mutant
but not with wild type mtDNAwas demonstrated for recombi-
FIGURE 5.Theeffect of recombinant RNAonheteroplasmy level in transfected cybrid cells.A, timedependence of A13514Gmutation heteroplasmy level
(axis Y) followed during 7–8 days. D0–D8, days after transfection of cells with different recombinant molecules.Mut, mock-transfected cybrid A13514G cells;
WT, mock-transfected 143B cells; FD20L, FD20H, or FD20L-DNA, cybrid cells transfected with corresponding recombinant molecule; Fibro 20H, primary
fibroblasts transfectedwith FD20H RNA. Data are expressed asmean S.D. for 3–5 independent experiments. Shown is an unpaired t test between values for
mutant and transfected cells; *, p	 0.02; **, p	 0.003; ***, p	 0.0009. B, an example of restriction fragment length polymorphism (RFLP) analysis for DNA
samples isolated in 3–8 days (as indicated above) after cybrid cell transfection with recombinant molecules indicated at the left. Digestion control was
performed for each reaction, as shown at the right panel. For this, 600-bp PCR fragment of mtDNA was cleaved by HaeIII to 350- and 250-bp fragments in the
same tube as 125-bp PCR fragment spanningA13514Gmutation site. TheA13514Gmutation creates anHaeIII-specific cleavage site, giving the fragment of 80
bp. Fragment size is indicated for each panel. C, evaluation of total and energised mitochondria content in 143B (wild type) and cybrid cells (A13514G)
transfectedwith RNAFD20Hduring 8days after cell transfection.MitoTrackerGreen (left panel) and TMRM (right panel) fluorescencenormalized to thenumber
of cells; values of wild type cells were taken as 1.
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nant RNA molecules. In the present study, we investigated
whether this strategy can be extended to pointmutations in the
mitochondrial genome. The first question we addressed was as
follows: could a recombinant RNA importable into human
mitochondria anneal in a specific way with only the mutant
mtDNA containing a point mutation but not with wild type?
Using Southern hybridization under conditions designed to
approximate the intracellular ionic environment, we demon-
strated that the sequence of 20 nucleotides corresponding to
H-strand of the mutated (A13514G) region of mtDNA
(FD20H) can discriminate between fragments of mutant and
wild typemtDNA.Thiswas rather surprising, because themelt-
ing temperature predictions for hybrids between recombinant
RNAs and mutated or wild type mtDNA (Table 1) show Tm
values 37 °C. Thus, all RNA molecules tested are likely to
anneal to mutant and wild type mtDNA fragments in the per-
missive conditions applied. According to the Tm predictions,
we have started our experiments with shorter insertions of
8–10 nucleotides, which should anneal to mutant but not to
wild type mtDNA. Surprisingly, we were not able to detect any
signal with these RNA molecules used as probes for Southern
blot hybridization and no effect on heteroplasmy level in trans-
fected cells (data not shown). Then, we gradually increased the
length of the complementary part from11 to 25 nt and obtained
specific hybridization (Fig. 2) for molecules containing 16- and
20-nt insertions. We suppose that the discrepancy between
predictions and experimental data is due to the absence of soft-
ware adapted to calculate the Tm of RNA-DNA duplexes con-
taining a mismatch. Another possible explanation consists in
formation of alternative secondary structures in RNA mole-
cules that cannot be predicted by available software.
Another interesting issue is that the hybridization of RNA
containing an insertion of the same length corresponding to the
complementary L-strand of mtDNA (FD20L) was much less
selective. This discrepancy can be explained by basemismatch-
es: for FD20H, C-A pairing decreases the Tm of hybridization
with wild type mtDNA by 10 °C (Table 1) compared with
mutant mtDNA (predicted by IDT Sci-Tools OligoAnalyser
software (version 3.1) for mismatch containing hybrids). In
contrast, for FD20L, G-T pairing decreases Tm by only 5.5 °C
and allows annealing of FD20L RNA with both mtDNA frag-
ments at 37 °C. The above data show that a point mutation can
be selectively addressed by RNA containing a 20-nucleotide
stretch; however, for transitions A to G (in L-strand of
mtDNA), sequences corresponding to H-strand would have a
more selective effect and vice versa, for G to A transitions, only
L-strand sequences should be used.
Pathogenic Mutation in ND5 Gene—mtDNA mutation
A13514G, which we used as a model in the present study, is
localized in NADH dehydrogenase ND5 subunit of the respira-
tory complex I. This is the first and largest enzyme of the
respiratory chain (45 subunits, total size  1 MDa), coupling
electron transfer between NADH and ubiquinone to the trans-
location of four protons across the inner mitochondrial mem-
brane (32). The L-shaped complex consists of hydrophilic and
membrane domains. Three largest transmembrane subunits
ND2, -4, and -5 at the far end of the membrane arm are homol-
ogous to each other and likely participate in the conformation-
coupled proton translocation (33). Mutation A13514G induces
amino acid replacement D393G localized in a very conserved
region of ND5 transmembrane helix 12 (34, 35), forming the
second half of the proton channel, and is involved in a cascade
of conformational changes leading to proton translocation.
Therefore, any mutation exchanging the negatively charged
Asp-393 to uncharged amino acid residue could disturb the
transport of the proton through the ND5 subunit channel of
respiratory complex I.
The ND5 gene turned out to be mutated frequently (30).
Point mutation A13514G-inducing amino acid replacement
D393G has been detected in four unrelated patients with
MELAS-like and Leigh syndromes (19, 36, 37). Another transi-
tion, the frequently reported and well documented G13513A,
affects the same Asp-393 residue in the ND5 gene, but the
amino acid replacement is different, D393N (reviewed in Ref.
30). A prominent clinical feature detected in patientswith these
mutations was a visual loss due to optic atrophy, indicating an
exquisite sensitivity of the optic nerve to damage caused by
alteration of the ND5 Asp-393 residue (38). Thus, search for
Asp-393 mutations has been proposed to be a part of the rou-
tine screening for mitochondrial disorders (19).
More recently, among the patients with Leigh-like syndrome
and D393N mutation in ND5, several cases were reported
characterized by normal complex I activity in muscle (36, 39).
The authors suggested that the relatively low mutant hetero-
plasmy and normal respiratory chain activities inmuscle do not
necessarily represent the situation in affected tissue such as
brain and/or optic nerve. Thus, even lowmutation load in Asp-
393 in the presence of normal respiratory chain analysis may be
considered as pathogenic (36), illustrating the complexities of
correlating A13514G heteroplasmy levels with biochemical
phenotype in patient’s muscle and fibroblasts. This can be a
characteristic feature of NADH dehydrogenase complex
because it was recently demonstrated that even a low dose of
wild type ND6 gene is sufficient to drive assembly of near nor-
mal levels of complex I (6). All of these data taken together
indicate that a low load of mutation A13514G might cause a
functional defect of ND5 protein, but this defect would be very
low and hardly noticeable. This is exactly the case of cells used
in the present study.
Effect of Imported RNAs on mtDNA Heteroplasmy—As we
have shown previously, mitochondrially imported anti-replica-
tive RNAs can cause a replication stalling at the site of RNA
annealing to the mutant mtDNA because of slowdown of the
TABLE 1
Melting temperature predictions for hybrids between recombinant








FD16L 16 48.4 °C 40.2 °C 8.2 °C
FD16H 16 48.4 °C 35.0 °C 13.4 °C
FD20L 20 54.9 °C 49.3 °C 5.6 °C
FD20H 20 52.8 °C 42.9 °C 9.9 °C
FD25L 25 59.0 °C 54.9 °C 4.1 °C
FD25H 25 59.0 °C 52.2 °C 6.8 °C
a Shown are values predicted by IDT Sci-Tools OligoAnalyser software (version
3.1) for mismatch containing DNA-DNA hybrids. 
Tm, predicted decrease of
Tm for wild type mtDNA compared with mutated mtDNA.
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replication fork progression (15). Nevertheless, we obtained
only a transient shift of heteroplasmy in cells bearing a large
deletion in mtDNA, the initial heteroplasmy level being
restored in 6–8 days after cell transfectionwith anti-replicative
RNA. This can be explained by recombinant RNA degradation,
followed by preferential replication of shorter mitochondrial
genomes bearing deletion, due to the previously reported effect
of “replicative advantage of deleted mtDNA” (40). In the pres-
ent study, we successfully obtained a stable decrease of the pro-
portion of mtDNA molecules containing ND5 point mutation
after transfection of cybrid cells and primary fibroblasts with
anti-replicative RNAFD20H (Fig. 5). Because no differencewas
expected in the rate of replication for wild type and mutant
mtDNA, we can suggest that even after degradation of recom-
binant RNA, the induced shift in ND5 point mutation hetero-
plasmy level may become stable. The maintenance of wild type
mtDNA enrichment was previously reported for several muta-
tions (41, 42).
Among several anti-replicative recombinant molecules,
characterized by comparable stability in cells and mitochon-
drial import efficiency (Fig. 4), only FD20Hwas able to induce a
prominent heteroplasmy shift. This RNA molecule demon-
strated the highest ability to discriminate between mutant and
wild type mtDNA (Fig. 2). The chimeric molecule, containing
the same sequence of the insertion part as FD20H, but in the
form of DNA, was not capable to shift the heteroplasmy level
(Fig. 5). These data provide an additional proof of recombinant
RNA action at the level of mtDNA replication because it was
suggested that mitochondrial replisome helicase can separate
DNA-DNA hybrids but not regions of short RNA-DNA hy-
brids in the mtDNA D-loop (43). Thus, only mitochondrially
imported RNA (but not DNA) molecules are likely to function
as anti-replicative agents in human mitochondria.
Cybrid cells used in the present study, containing 35% of
mtDNA molecules bearing the A13514G mutation, were
almost asymptomatic, characterized by a very slight decrease of
all of themeasurable parameters as oxygen consumption, levels
ofATP, reactive oxygen species, and complex I enzymatic activ-
ity compared with wild type 143B cell line (data not shown).
Nevertheless, we observed a prominent decrease of amount of
mitochondria in cybrid cells, measured by use of MitoTracker
Green, a mitochondria-selective fluorescent label, accumu-
lating in the matrix (Fig. 5C) (44). Notably, transfection with
anti-replicative RNA FD20H, leading to an important
decrease of the level ofND5 pointmutation, caused, at the same
time, a recovery of mitochondrial content. Unexpectedly, if the
MitoTracker Green fluorescence increased gradually from day
4 to day 6 post transfection and then reached a plateau, the shift
of the TMRM fluorescence between days 4 and 5 was rather
sharp. Thus, we observe some temporary hyperpolarization of
mitochondria only at day 5 post transfection. We can hypoth-
esize that following the heteroplasmy decrease observed for
ND5 cybrid cells in 3–4 days post transfection, the synthesis of
increased amounts of normal, fully active ND5 protein might
create a temporary unbalance in the assembly of respiratory
complexes, resulting in a rise of the basal production of reactive
oxygen species (at the 5th day) and increasing mitochondrial
biogenesis (days 6–8).
All of our data indicate on the possibility to obtain a curative
effect of mitochondrial dysfunctions in human cells by a het-
eroplasmy shift induced by short RNAmolecules targeted into
mitochondria. Although the inhibitory effect was partial, it may
have a long term therapeutic interest because only high levels of
mutations in human mtDNA become pathogenic. The valida-
tion of the anti-replicative RNA strategy for a pointmutation in
mtDNA in cultured human cells can be considered as an impor-
tant step to further develop an efficient therapy of mitochon-
drial diseases.
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